Skip to main content

Advertisement

Table 1 KRAS status as a prognostic marker in lung cancer

From: KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Reference Type of study Patients tested for KRAS Patients by KRAS status Results (KRAS-mut vs KRAS-wt)
KRAS-mut KRAS-wt
Mascaux et al., 2005 [61] Pooled analysis 3620 (stage I-IV) 652 2968 HR for OS 1.35 (1.16–1.56), p = 0.01
Sheperd et al., 2013 [62] Pooled analysis 1543 (stage I-III) 300 1246 HR for OS 1.17, 95% CI 0.96 to 1.42, p = 0.12
Zer et al., 2016 [63] Pooled analysis 577 (stage IIIB-IV) 120 457 HR for OS 1.09, 95% CI 0.85–1.41, p = 0.48
Pan et al., 2016 [64] Pooled analysis 13,103 (stage I-IV) 2374 10,729 HR for OS 1.56, 95% CI 1.39–1.76, p = 0.00
Svaton et al., 2016 [66] Individual study 129 (stage IIIB-IV) 39 90 OS: 16.1 months for wt-KRAS and 7.2 for mut-KRAS
PFS: 2.3 for wt-KRAS and 1.6 for mut-KRAS
Fan et al., 2017 [65] Pooled analysis 658 (advanced NSCLC) 93 565 HR for PFS 1.83, 95% CI 1.40–2.40, p < 0.0001
693 (advanced NSCLC) 106 587 HR for OS 2.07, 95% CI 1.54–2.78, p < 0.0001